The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14): Protocol for a phase II study

Yuhki Koga; Shingo Baba; Reiji Fukano; Katsumasa Nakamura; Toshinori Soejima; Naoko Maeda; Shosuke Sunami; Junichi Ueyama; Tetsuo Mitsui; Takeshi Mori; Tomoo Osumi; Masahiro Sekimizu; Kentaro Ohki; Fumiko Tanaka; Michi Kamei; Naoto Fujita; Tetsuya Mori; Akiko M. Saito; Akiko Kada; Ryoji Kobayashi

The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14): Protocol for a phase II study

Yuhki Koga
, Shingo Baba
, Reiji Fukano
, Katsumasa Nakamura
, Toshinori Soejima
, Naoko Maeda
, Shosuke Sunami
, Junichi Ueyama
, Tetsuo Mitsui
, Takeshi Mori
, Tomoo Osumi
, Masahiro Sekimizu
, Kentaro Ohki
, Fumiko Tanaka
, Michi Kamei
, Naoto Fujita
, Tetsuya Mori
, Akiko M. Saito
, Akiko Kada
, Ryoji Kobayashi

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

抄録

This trial enrolls patients with untreated Hodgkin's lymphoma aged<20 years at diagnosis and examines the effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two completed cycles of combination chemotherapy are negative. It thereby aims to determine whether patients who truly require radiation therapy can be identified by FDG-PET. If so, this modality could be used to omit radiation therapy for all other patients, decreasing the risk of serious long-term complications without affecting survival rates. The outcomes of patients for whom FDG-PET is used to assess early treatment response will also be determined.

本文言語	英語
ページ（範囲）	437-440
ページ数	4
ジャーナル	Acta medica Okayama
巻	72
号	4
出版ステータス	出版済み - 2018

!!!All Science Journal Classification (ASJC) codes

生化学、遺伝学、分子生物学一般

他のファイルとリンク

フィンガープリント

「The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14): Protocol for a phase II study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Koga, Y., Baba, S., Fukano, R., Nakamura, K., Soejima, T., Maeda, N., Sunami, S., Ueyama, J., Mitsui, T., Mori, T., Osumi, T., Sekimizu, M., Ohki, K., Tanaka, F., Kamei, M., Fujita, N., Mori, T., Saito, A. M., Kada, A., & Kobayashi, R. (2018). The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14): Protocol for a phase II study. Acta medica Okayama, 72(4), 437-440.

Koga, Y, Baba, S, Fukano, R, Nakamura, K, Soejima, T, Maeda, N, Sunami, S, Ueyama, J, Mitsui, T, Mori, T, Osumi, T, Sekimizu, M, Ohki, K, Tanaka, F, Kamei, M, Fujita, N, Mori, T, Saito, AM, Kada, A & Kobayashi, R 2018, 'The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14): Protocol for a phase II study', Acta medica Okayama, vol. 72, no. 4, pp. 437-440.

@article{b1611890cec94ba7bb14936cd34956e6,

title = "The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14): Protocol for a phase II study",

abstract = "This trial enrolls patients with untreated Hodgkin's lymphoma aged<20 years at diagnosis and examines the effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two completed cycles of combination chemotherapy are negative. It thereby aims to determine whether patients who truly require radiation therapy can be identified by FDG-PET. If so, this modality could be used to omit radiation therapy for all other patients, decreasing the risk of serious long-term complications without affecting survival rates. The outcomes of patients for whom FDG-PET is used to assess early treatment response will also be determined.",

author = "Yuhki Koga and Shingo Baba and Reiji Fukano and Katsumasa Nakamura and Toshinori Soejima and Naoko Maeda and Shosuke Sunami and Junichi Ueyama and Tetsuo Mitsui and Takeshi Mori and Tomoo Osumi and Masahiro Sekimizu and Kentaro Ohki and Fumiko Tanaka and Michi Kamei and Naoto Fujita and Tetsuya Mori and Saito, \{Akiko M.\} and Akiko Kada and Ryoji Kobayashi",

note = "Publisher Copyright: {\textcopyright}2018 by Okayama University Medical School.",

year = "2018",

language = "English",

volume = "72",

pages = "437--440",

journal = "Acta medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "4",

}

TY - JOUR

T1 - The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with hodgkin's lymphoma (HL-14)

T2 - Protocol for a phase II study

AU - Koga, Yuhki

AU - Baba, Shingo

AU - Fukano, Reiji

AU - Nakamura, Katsumasa

AU - Soejima, Toshinori

AU - Maeda, Naoko

AU - Sunami, Shosuke

AU - Ueyama, Junichi

AU - Mitsui, Tetsuo

AU - Mori, Takeshi

AU - Osumi, Tomoo

AU - Sekimizu, Masahiro

AU - Ohki, Kentaro

AU - Tanaka, Fumiko

AU - Kamei, Michi

AU - Fujita, Naoto

AU - Mori, Tetsuya

AU - Saito, Akiko M.

AU - Kada, Akiko

AU - Kobayashi, Ryoji

PY - 2018

Y1 - 2018

N2 - This trial enrolls patients with untreated Hodgkin's lymphoma aged<20 years at diagnosis and examines the effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two completed cycles of combination chemotherapy are negative. It thereby aims to determine whether patients who truly require radiation therapy can be identified by FDG-PET. If so, this modality could be used to omit radiation therapy for all other patients, decreasing the risk of serious long-term complications without affecting survival rates. The outcomes of patients for whom FDG-PET is used to assess early treatment response will also be determined.

AB - This trial enrolls patients with untreated Hodgkin's lymphoma aged<20 years at diagnosis and examines the effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two completed cycles of combination chemotherapy are negative. It thereby aims to determine whether patients who truly require radiation therapy can be identified by FDG-PET. If so, this modality could be used to omit radiation therapy for all other patients, decreasing the risk of serious long-term complications without affecting survival rates. The outcomes of patients for whom FDG-PET is used to assess early treatment response will also be determined.

UR - https://www.scopus.com/pages/publications/85051869337

UR - https://www.scopus.com/pages/publications/85051869337#tab=citedBy

M3 - Article

C2 - 30140095

AN - SCOPUS:85051869337

SN - 0386-300X

VL - 72

SP - 437

EP - 440

JO - Acta medica Okayama

JF - Acta medica Okayama

IS - 4

ER -